Parastu Kasaie1, Jeff Pennington, Maunank S Shah, Stephen A Berry, Danielle German, Colin P Flynn, Chris Beyrer, David W Dowdy. 1. *Departments of Health, Behavior and Society; †Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; ‡Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD; and §Department of Health and Mental Hygiene (DHMH), Center for HIV Surveillance, Epidemiology and Evaluation, Baltimore, MD.
Abstract
OBJECTIVES: Preexposure prophylaxis (PrEP) is recommended for preventing HIV infection among individuals at high risk, including men who have sex with men (MSM). Although its individual-level efficacy is proven, questions remain regarding population-level impact of PrEP implementation. DESIGN: We developed an agent-based simulation of HIV transmission among MSM, accounting for demographics, sexual contact network, HIV disease stage, and use of antiretroviral therapy. We use this framework to compare PrEP delivery strategies in terms of impact on HIV incidence and prevalence. RESULTS: The projected reduction in HIV incidence achievable with PrEP reflects both population-level coverage and individual-level adherence (as a proportion of days protected against HIV transmission). For example, provision of PrEP to 40% of HIV-negative MSM reporting more than one sexual partner in the last 12 months, taken with sufficient adherence to provide protection on 40% of days, can reduce HIV incidence by 9.5% (95% uncertainty range: 8%-11%) within 5 years. However, if this could be increased to 80% coverage on 80% of days (eg, through mass campaigns with a long-acting injectable formulation), a 43% (42%-44%) reduction in HIV incidence could be achieved. Delivering PrEP to MSM at high risk for HIV acquisition can augment population-level impact up to 1.8-fold. CONCLUSIONS: If highly ambitious targets for coverage and adherence can be achieved, PrEP can substantially reduce HIV incidence in the short-term. Although the reduction in HIV incidence largely reflects the proportion of person-years protected, the efficiency of PrEP delivery can be enhanced by targeting high-risk populations.
OBJECTIVES: Preexposure prophylaxis (PrEP) is recommended for preventing HIV infection among individuals at high risk, including men who have sex with men (MSM). Although its individual-level efficacy is proven, questions remain regarding population-level impact of PrEP implementation. DESIGN: We developed an agent-based simulation of HIV transmission among MSM, accounting for demographics, sexual contact network, HIV disease stage, and use of antiretroviral therapy. We use this framework to compare PrEP delivery strategies in terms of impact on HIV incidence and prevalence. RESULTS: The projected reduction in HIV incidence achievable with PrEP reflects both population-level coverage and individual-level adherence (as a proportion of days protected against HIV transmission). For example, provision of PrEP to 40% of HIV-negative MSM reporting more than one sexual partner in the last 12 months, taken with sufficient adherence to provide protection on 40% of days, can reduce HIV incidence by 9.5% (95% uncertainty range: 8%-11%) within 5 years. However, if this could be increased to 80% coverage on 80% of days (eg, through mass campaigns with a long-acting injectable formulation), a 43% (42%-44%) reduction in HIV incidence could be achieved. Delivering PrEP to MSM at high risk for HIV acquisition can augment population-level impact up to 1.8-fold. CONCLUSIONS: If highly ambitious targets for coverage and adherence can be achieved, PrEP can substantially reduce HIV incidence in the short-term. Although the reduction in HIV incidence largely reflects the proportion of person-years protected, the efficiency of PrEP delivery can be enhanced by targeting high-risk populations.
Authors: Ferdinand Wnm Wit; Daniel H Blanckenberg; Kees Brinkman; Jan M Prins; Marchina E van der Ende; Margriet Me Schneider; Jan-Willem Mulder; Frank de Wolf; Joep Ma Lange Journal: AIDS Date: 2005-02-18 Impact factor: 4.177
Authors: Chris Beyrer; Stefan D Baral; Frits van Griensven; Steven M Goodreau; Suwat Chariyalertsak; Andrea L Wirtz; Ron Brookmeyer Journal: Lancet Date: 2012-07-20 Impact factor: 79.321
Authors: Spencer Lieb; Stephen J Fallon; Samuel R Friedman; Daniel R Thompson; Gary J Gates; Thomas M Liberti; Robert M Malow Journal: Public Health Rep Date: 2011 Jan-Feb Impact factor: 2.792
Authors: Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Frangiscos Sifakis; John B Hylton; Colin Flynn; Liza Solomon; Duncan A Mackellar; Linda A Valleroy; David D Celentano Journal: J Acquir Immune Defic Syndr Date: 2007-11-01 Impact factor: 3.731
Authors: Brandon D L Marshall; Magdalena M Paczkowski; Lars Seemann; Barbara Tempalski; Enrique R Pouget; Sandro Galea; Samuel R Friedman Journal: PLoS One Date: 2012-09-13 Impact factor: 3.240
Authors: Philip A Chan; William C Goedel; Amy S Nunn; Genoviva Sowemimo-Coker; Omar Galárraga; Mattia Prosperi; Rupa Patel; Leandro Mena; Madeline C Montgomery; Brandon D L Marshall Journal: AIDS Patient Care STDS Date: 2019-10 Impact factor: 5.078
Authors: Bryan A Kutner; Jane M Simoni; Kevin M King; Steven M Goodreau; Andrea Norcini Pala; Emma Creegan; Frances M Aunon; Stefan D Baral; B R Simon Rosser Journal: J Sex Med Date: 2020-01-10 Impact factor: 3.802
Authors: Anthony Nguyen; Emmanuel Fulgence Drabo; Wendy H Garland; Corrina Moucheraud; Ian W Holloway; Arleen Leibowitz; Sze-Chuan Suen Journal: AIDS Patient Care STDS Date: 2022-08 Impact factor: 5.944
Authors: Bobby J Calder; Robert J Schieffer; Ewa Bryndza Tfaily; Richard D'Aquila; George J Greene; Alex Carballo-Diéguez; Rebecca Giguere; Patrick F Kiser; Thomas J Hope Journal: AIDS Res Hum Retroviruses Date: 2018-10 Impact factor: 2.205
Authors: Elizabeth C Pasipanodya; Michael J Li; Sonia Jain; Xiaoying Sun; Jessica Tobin; Eric Ellorin; Michael Dube; Eric S Daar; Katya Corado; Joel Milam; Jill Blumenthal; Sheldon H Morris; David J Moore Journal: AIDS Behav Date: 2020-11
Authors: Sophia Bartels; Ingrid Castillo; Dirk A Davis; Lisa B Hightow-Weidman; Kathryn E Muessig; Cesar Galindo; Clare Barrington Journal: AIDS Behav Date: 2021-05-08